Study identifier:D0819C00005
ClinicalTrials.gov identifier:NCT03590938
EudraCT identifier:N/A
CTIS identifier:N/A
Lynparza Tablets 100mg, 150mg CEI, Investigation on development of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy
Breast Cancer
N/A
No
-
All
111
Observational
N/A
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Apr 2022 by AstraZeneca
AstraZeneca
-
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.
Location
Location
Aomori, Japan, D0819C00005
Location
Miyagi, Japan, D0819C00005
Location
Gunma, Japan, D0819C00005
Location
Saitama, Japan, D0819C00005
Location
Chiba, Japan, D0819C00005
Location
Tokyo, Japan, D0819C00005
Location
Kanagawa, Japan, D0819C00005
Location
Fukui, Japan, D0819C00005
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.